April 11, 2019
FDA to require label changes on how to safely decrease opioids in physically dependent patients
Editor's Note
The Food & Drug Administration (FDA) on April 9 issued a Drug Safety Announcement saying it has received reports of serious harm in patients who are physically dependent on opioid pain medications and suddenly have them discontinued or rapidly decreased.
Because of these reports, the FDA is requiring changes to prescribing information, which will provide expanded guidance on how to safely decrease the dose in patients when the dose is to be decreased or the medication is to be discontinued.
Free Daily News
- Contribute to perioperative education with the 2024 OR Manager Salary/Career Survey
- Supply chain stability improves, but threats remain
- Private equity healthcare ownership draws new scrutiny
- Share your expertise! Topics, speakers sought for 2025 ORBMC
- FDA approves imaging drug for detecting cancer after lumpectomy
- Penn Medicine anesthesia, waste initiatives boost OR sustainability
- Survey assesses continued impact of Change Healthcare cyberattack
- WHO sounds alarm on potential spread of bird flu
- Allison Massari to deliver hopeful, empowering keynote address at OR Manager Conference 2024
- Neurosurgery trial: Early evacuation improves long-term hemorrhage outcomes
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging